Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 57-62 , 15 May 2010

Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts

  • Elaine Kingwell

      Affiliations

    • Faculty of Medicine (Neurology), Multiple Sclerosis Program, UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    • Corresponding Author InformationCorresponding author. Faculty of Medicine (Neurology), UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, Canada V6T 2B5. Tel.: +1 604 822 7617; fax: +1 604 822 7897.
    • ,
  • Alexander L. Leung

      Affiliations

    • Faculty of Medicine (Neurology), Multiple Sclerosis Program, UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    • ,
  • Elaine Roger

      Affiliations

    • Hôpital Notre-Dame du CHUM, University of Montreal, Pavillion Champlain, 1560 Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    • ,
  • Pierre Duquette

      Affiliations

    • Hôpital Notre-Dame du CHUM, University of Montreal, Pavillion Champlain, 1560 Sherbrooke East, Montreal, Quebec, Canada H2L 4M1
    • ,
  • Peter Rieckmann

      Affiliations

    • Faculty of Medicine (Neurology), Multiple Sclerosis Program, UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    • ,
  • Helen Tremlett

      Affiliations

    • Faculty of Medicine (Neurology), Multiple Sclerosis Program, UBC Hospital, 2211 Wesbrook Mall, University of British Columbia, Vancouver, BC, Canada V6T 2B5
    • ,
  • the UBC MS Neurologists

      Affiliations

    • The UBC MS Clinic Neurologists (in alphabetical order): D. Adams, D. Craig, L. Daly, V. Devonshire, S. Hashimoto, O. Hiebiceck, J. Hooge, B. Jones, L. Kastrukoff, S. Meckling, J. Oger, D. Parton, D. Paty, P. Smyth, W. Shtybel, and T. Traboulsee.

Received 10 December 2009 ,Revised 2 February 2010 ,Accepted 8 February 2010.

References 

  1. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol. 2006;63:614–619
  2. National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease Management Consensus Statement. 2007: Available from: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/treatments/index.aspx (accessed 22nd Jan 2010).
  3. Pittock SJ, Weinshenker BG, Noseworthy JH, Lucchinetti CF, Keegan M, Wingerchuk DM, et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol. 2006;63:611–614
  4. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000;343:898–904
  5. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576–1582
  6. Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult. Scler. 2003;9:585–591
  7. Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, et al. IM interferon beta-1a delays definite multiple sclerosis 5years after a first demyelinating event. Neurology. 2006;66:678–684
  8. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389–397
  9. Poser CM, Benedikz J, Hibberd PL. The epidemiology of multiple sclerosis: the Iceland model. Onset-adjusted prevalence rate and other methodological considerations. J. Neurol. Sci. 1992;111:143–152
  10. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult. Scler. 1999;5:293–296
  11. Celius EG, Vandvik B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur. J. Neurol. 2001;8:463–469
  12. Barnett MH, Williams DB, Day S, Macaskill P, McLeod JG. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J. Neurol. Sci. 2003;213:1–6
  13. Pugliatti M, Riise T, Sotgiu MA, Sotgiu S, Satta WM, Mannu L, et al. Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia. Neuroepidemiology. 2005;25:129–134
  14. Sloka JS, Pryse-Phillips WE, Stefanelli M. Incidence and prevalence of multiple sclerosis in Newfoundland and Labrador. Can. J. Neurol. Sci. 2005;32:37–42
  15. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5:932–936
  16. Hader WJ, Yee IM. Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology. 2007;69:1224–1229
  17. Debouverie M, Pittion-Vouyovitch S, Louis S, Roederer T, Guillemin F. Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France. Mult. Scler. 2007;13:962–967
  18. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129–135
  19. Esbjerg S, Keiding N, Koch-Henriksen N. Reporting delay and corrected incidence of multiple sclerosis. Stat. Med. 1999;18:1691–1706
  20. Koch-Henriksen N, Bronnum-Hansen H, Hyllested K. Incidence of multiple sclerosis in Denmark 1948–1982: a descriptive nationwide study. Neuroepidemiology. 1992;11:1–10
  21. Fasbender P, Kolmel HW. Incidence of multiple sclerosis in the urban area of Erfurt, Thuringia, Germany. Neuroepidemiology. 2008;30:147–151
  22. Midgard R, Riise T, Svanes C, Kvale G, Nyland H. Incidence of multiple sclerosis in More and Romsdal, Norway from 1950 to 1991. An age–period–cohort analysis.. Brain. 1996;119(Pt 1):203–211
  23. Gronning M, Riise T, Kvale G, Nyland H, Larsen JP, Aarli JA. Incidence of multiple sclerosis in Hordaland, western Norway: a fluctuating pattern. Neuroepidemiology. 1991;10:53–61
  24. Sumelahti ML, Tienari PJ, Hakama M, Wikstrom J. Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses. J Neurol Neurosurg Psychiatry. 2003;74:25–28
  25. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  26. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001;50:121–127
  27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452
  28. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology. 1955;5:580–583
  29. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology. 2005;65:1066–1070
  30. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009;72:117–124
  31. McDonnell GV, Hawkins SA. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J. Neurol. Neurosurg. Psychiatry. 1998;64:451–454
  32. Wolinsky JS. The diagnosis of primary progressive multiple sclerosis. J. Neurol. Sci. 2003;206:145–152
  33. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6:903–912
  34. Sumelahti ML, Tienari PJ, Wikstrom J, Salminen TM, Hakama M. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult. Scler. 2002;8:350–355
  35. Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122(Pt 4):625–639
  36. Sorensen TL, Frederiksen JL, Bronnum-Hansen H, Petersen HC. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology. 1999;53:473–478
  37. Nicoletti A, Lo Bartolo ML, Lo Fermo S, Cocuzza V, Panetta MR, Marletta C, et al. Prevalence and incidence of multiple sclerosis in Catania, Sicily. Neurology. 2001;56:62–66
  38. Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Pirastru MI, Murgia B, et al. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol. Scand. 2001;103:20–26
  39. Dahl OP, Aarseth JH, Myhr KM, Nyland H, Midgard R. Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurol. Scand. 2004;109:378–384
  40. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006;66:172–177

PII: S0022-510X(10)00064-X

doi: 10.1016/j.jns.2010.02.007

Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 57-62 , 15 May 2010

Article Tools

* Image Usage & Resolution